IBDEI39K ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,52091,1,4,0)
 ;;=4^A81.9
 ;;^UTILITY(U,$J,358.3,52091,2)
 ;;=^5000414
 ;;^UTILITY(U,$J,358.3,52092,0)
 ;;=A81.09^^193^2517^8
 ;;^UTILITY(U,$J,358.3,52092,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52092,1,3,0)
 ;;=3^Creutzfeldt-Jakob Disease NEC
 ;;^UTILITY(U,$J,358.3,52092,1,4,0)
 ;;=4^A81.09
 ;;^UTILITY(U,$J,358.3,52092,2)
 ;;=^5000410
 ;;^UTILITY(U,$J,358.3,52093,0)
 ;;=A81.00^^193^2517^9
 ;;^UTILITY(U,$J,358.3,52093,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52093,1,3,0)
 ;;=3^Creutzfeldt-Jakob Disease,Unspec
 ;;^UTILITY(U,$J,358.3,52093,1,4,0)
 ;;=4^A81.00
 ;;^UTILITY(U,$J,358.3,52093,2)
 ;;=^5000409
 ;;^UTILITY(U,$J,358.3,52094,0)
 ;;=A81.01^^193^2517^10
 ;;^UTILITY(U,$J,358.3,52094,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52094,1,3,0)
 ;;=3^Creutzfeldt-Jakob Disease,Variant
 ;;^UTILITY(U,$J,358.3,52094,1,4,0)
 ;;=4^A81.01
 ;;^UTILITY(U,$J,358.3,52094,2)
 ;;=^336701
 ;;^UTILITY(U,$J,358.3,52095,0)
 ;;=A81.89^^193^2517^7
 ;;^UTILITY(U,$J,358.3,52095,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52095,1,3,0)
 ;;=3^Atypical Virus Infections of CNS NEC
 ;;^UTILITY(U,$J,358.3,52095,1,4,0)
 ;;=4^A81.89
 ;;^UTILITY(U,$J,358.3,52095,2)
 ;;=^5000413
 ;;^UTILITY(U,$J,358.3,52096,0)
 ;;=A81.2^^193^2517^27
 ;;^UTILITY(U,$J,358.3,52096,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52096,1,3,0)
 ;;=3^Progressive Multifocal Leukoencephalopathy
 ;;^UTILITY(U,$J,358.3,52096,1,4,0)
 ;;=4^A81.2
 ;;^UTILITY(U,$J,358.3,52096,2)
 ;;=^5000411
 ;;^UTILITY(U,$J,358.3,52097,0)
 ;;=B20.^^193^2517^17
 ;;^UTILITY(U,$J,358.3,52097,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52097,1,3,0)
 ;;=3^HIV Disease w/ Dementia w/ Behavioral Disturbances
 ;;^UTILITY(U,$J,358.3,52097,1,4,0)
 ;;=4^B20.
 ;;^UTILITY(U,$J,358.3,52097,2)
 ;;=^5000555^F02.81
 ;;^UTILITY(U,$J,358.3,52098,0)
 ;;=B20.^^193^2517^18
 ;;^UTILITY(U,$J,358.3,52098,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52098,1,3,0)
 ;;=3^HIV Disease w/ Dementia w/o Behavioral Disturbances
 ;;^UTILITY(U,$J,358.3,52098,1,4,0)
 ;;=4^B20.
 ;;^UTILITY(U,$J,358.3,52098,2)
 ;;=^5000555^F02.80
 ;;^UTILITY(U,$J,358.3,52099,0)
 ;;=F10.27^^193^2517^1
 ;;^UTILITY(U,$J,358.3,52099,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52099,1,3,0)
 ;;=3^Alcohol Dependence w/ Alcohol-Induced Persisting Dementia
 ;;^UTILITY(U,$J,358.3,52099,1,4,0)
 ;;=4^F10.27
 ;;^UTILITY(U,$J,358.3,52099,2)
 ;;=^5003095
 ;;^UTILITY(U,$J,358.3,52100,0)
 ;;=F19.97^^193^2517^29
 ;;^UTILITY(U,$J,358.3,52100,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52100,1,3,0)
 ;;=3^Psychoactive Substance Use w/ Persisting Dementia NEC
 ;;^UTILITY(U,$J,358.3,52100,1,4,0)
 ;;=4^F19.97
 ;;^UTILITY(U,$J,358.3,52100,2)
 ;;=^5003465
 ;;^UTILITY(U,$J,358.3,52101,0)
 ;;=F03.90^^193^2517^15
 ;;^UTILITY(U,$J,358.3,52101,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52101,1,3,0)
 ;;=3^Dementia w/o Behavioral Disturbance,Unspec
 ;;^UTILITY(U,$J,358.3,52101,1,4,0)
 ;;=4^F03.90
 ;;^UTILITY(U,$J,358.3,52101,2)
 ;;=^5003050
 ;;^UTILITY(U,$J,358.3,52102,0)
 ;;=G30.0^^193^2517^2
 ;;^UTILITY(U,$J,358.3,52102,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52102,1,3,0)
 ;;=3^Alzheimer's Disease w/ Early Onset
 ;;^UTILITY(U,$J,358.3,52102,1,4,0)
 ;;=4^G30.0
 ;;^UTILITY(U,$J,358.3,52102,2)
 ;;=^5003805
 ;;^UTILITY(U,$J,358.3,52103,0)
 ;;=G30.1^^193^2517^3
 ;;^UTILITY(U,$J,358.3,52103,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52103,1,3,0)
 ;;=3^Alzheimer's Disease w/ Late Onset
